TITLE:
Therapeutic Efficacy of Genistein-Topotecan Combination Compared to Vitamin D3-Topotecan Combination in LNCaP Prostate Cancer Cells
AUTHORS:
Shreyasee Chakraborty, Bibiana Sandoval-Bernal, James Kumi-Diaka
KEYWORDS:
Topotecan; Genistein; Vitamin D; Prostate Cancer
JOURNAL NAME:
CellBio,
Vol.2 No.3,
September
17,
2013
ABSTRACT: Background: Prostate cancer is the most common cancer in men over the age of 60 in Western countries. An estimated 241,740
new cases of prostate cancer have been diagnosed in the United States in 2012 with a death
toll of 28,170. Varieties of natural phytochemicals such as genistein and
topotecan have shown potential chemotherapeutic capacities and are being used
to inhibit the growth and proliferation of cell in prostate cancer. Purpose of Study: In this study, we aim
to determine the efficacy of Vitamin D3-Topotecan combination
compared to Genistein-Topotecan in apoptosis induction in LNCaP prostate cancer
cells. Methods: LNCaP cells were
grown in complete RPMI medium and cultured at 37°C, 5% CO2 for 23 - 48 hrs to
achieve 70% - 80% confluence. The cells were then treated with
Genistein-Topotecan, Vitamin D3-Topotecan combination and TPT alone
for 24 - 48 hours. In addition, post-treatment assayed using: Trypan Blue
exclusion and MTT for cell viability, Ethidium bromide/Acridine orange to
determine apoptosis induction, Rhodamine 123/Ethidium bromide to differentiate
between viable, apoptotic, and necrotic cells, as well as to assess possible
apoptotic mechanism, and DNA fragmentation to discriminate between apoptotic
and necrotic cell death. Results: The overall data indicated the dose-and time-dependent cell death in the LNCaP
cells and apoptosis as the major mechanism of treatment-induced cell growth
arrest. Conclusion: The
Genistein-Topotecan combination treatment was significantly more efficacious in
growth inhibition of LNCaP cells compared to Vitamin D3-Topotecan or
Topotecan alone.